Neovasc (TSE:NVC) Lowered to Hold at Bloom Burton

Bloom Burton cut shares of Neovasc (TSE:NVCGet Rating) (NASDAQ:NVCN) from a buy rating to a hold rating in a report published on Wednesday morning, PriceTargets.com reports.

Separately, HC Wainwright lowered shares of Neovasc from a buy rating to a neutral rating in a report on Wednesday.

Neovasc Stock Performance

Neovasc has a 1-year low of C$0.49 and a 1-year high of C$6.07. The company’s 50 day moving average is C$1.78.

Neovasc (TSE:NVCGet Rating) (NASDAQ:NVCN) last released its quarterly earnings results on Thursday, November 10th. The company reported C($3.91) EPS for the quarter, missing the consensus estimate of C($3.67) by C($0.24). The company had revenue of C$1.21 million for the quarter, compared to analyst estimates of C$1.37 million.

Insider Activity at Neovasc

In other news, Director Paul Geyer acquired 3,000 shares of the business’s stock in a transaction on Friday, November 18th. The shares were purchased at an average cost of C$8.71 per share, with a total value of C$26,130.00. Following the acquisition, the director now directly owns 18,335 shares of the company’s stock, valued at C$159,697.85.

Neovasc Company Profile

(Get Rating)

Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.

Featured Articles

Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.